Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Author:

Pignatti Patrizia1,Visca Dina1,Zappa Martina2,Zampogna Elisabetta1,Saderi Laura3,Sotgiu Giovanni3,Centis Rosella1,Migliori Giovanni Battista1,Spanevello Antonio1

Affiliation:

1. Istituti Clinici Scientifici Maugeri, IRCCS

2. University of Insubria

3. University of Sassari

Abstract

Abstract Background High blood eosinophils seem to predict exacerbations and response to inhaled corticosteroids (ICS) treatment in patients with chronic obstructive pulmonary disease (COPD). The aim of our study was to prospectively evaluate for 2 years, blood and sputum eosinophils in COPD patients treated with bronchodilators only at recruitment. Methods COPD patients in stable condition treated with bronchodilators only underwent monitoring of lung function, blood and sputum eosinophils, exacerbations and comorbidities every 6 months for 2 years. ICS was added during follow-up when symptoms worsened. Results 63 COPD patients were enrolled: 53 were followed for 1 year, 41 for 2 years, 10 dropped-out. After 2 years, ICS was added in 12/41 patients (29%) without any statistically significant difference at time points considered. Blood and sputum eosinophils did not change during follow-up. Only FEV1/FVC at T0 was predictive of ICS addition during the 2 year-follow-up (OR:0.91; 95% CI: 0.83–0.99, p = 0.03). ICS addition did not impact on delta (T24-T0) FEV1, blood and sputum eosinophils and exacerbations. After 2 years, patients who received ICS had higher blood eosinophils than those in bronchodilator therapy (p = 0.042). Patients with history of ischemic heart disease increased blood eosinophils after 2 years [p = 0.03 for both percentage and counts]. Conclusions Almost 30% of mild/moderate COPD patients in bronchodilator therapy received ICS for worsened symptoms in a 2 year-follow-up. Only FEV1/FVC at T0 seems to predict ICS addition during follow-up. Blood and sputum eosinophils were not associated with worsened symptoms or exacerbations. History of ischemic heart disease seems to be associated with a progressive increase of blood eosinophils.

Publisher

Research Square Platform LLC

Reference39 articles.

1. Global Strategy for the Diagnosis Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD)., 2023. Available from: https://goldcopd.org/. Date last access: 2023/09/11.

2. Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients;Pignatti P;Respir Res,2019

3. Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting;Komura M;Can Respir J,2023

4. Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy;Chen S;Int J Chron Obstruct Pulmon Dis,2022

5. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation;Stockley RA;Am J Respir Crit Care Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3